Form 4: Opus Genetics Director, Sean Ainsworth, Receives Stock Grant and Options

Director Sean Ainsworth of Opus Genetics, Inc. reports acquisition of restricted stock units and stock options.

Summary

• Sean Ainsworth, a director at Opus Genetics, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On April 30, 2025, Ainsworth acquired 79,504 shares of common stock through a grant of restricted stock units.
• These restricted stock units vest upon the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent on continued service.
• Ainsworth also acquired options to purchase 79,592 shares of common stock at an exercise price of $0.95.
• These options vest under the same conditions as the restricted stock units and expire on April 29, 2035.
• Following these transactions, Ainsworth directly owns 167,862 shares of Opus Genetics, Inc.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock and options, which is generally viewed positively as it aligns management interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting conditions incentivize continued service and commitment to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Stock grants and options are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders and incentivize long-term growth.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in biotech companies.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing continued service.
• Comparing the size of the grant to similar companies would require further analysis of Opus Genetics' compensation policies and market capitalization.

Stakeholder Impact

• The grant of stock options and restricted stock units could positively impact shareholder value if the director's performance contributes to the company's success.
• The director is incentivized to act in the best interests of the company and its shareholders.

Next Steps

• The restricted stock units and stock options will vest according to the specified schedule, contingent on the director's continued service.

Key Dates

Keywords

Form 4, Opus Genetics, Sean Ainsworth, Director, Stock Options, Restricted Stock Units, Beneficial Ownership